Assessment and Management of Newly Diagnosed Classical Hodgkin Lymphoma: A Consensus Practice Statement from the Australasian Lymphoma Alliance.

The management of Hodgkin Lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment related morbidity is a constant source of concern, for physicians and patients alike. PET adapted therapy has been develop...

Full description

Bibliographic Details
Published in:Internal Medicine Journal
Main Authors: Cochrane, T, Campbell, B A, Gangatharan, S A, Latimer, M, Khor, R, Christie, Drh, Gilbertson, M, Ratnasingam, S, Palfreyman, E, Lee, H P, Trotman, J, Hertzberg, M, Dickinson, M
Format: Article in Journal/Newspaper
Language:English
Published: Australia 2021
Subjects:
Austin
Canada
Flinders
Northwest Territories
Online Access:https://hdl.handle.net/10137/11874
https://doi.org/10.1111/imj.15503
https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/34505342
Description
Summary:The management of Hodgkin Lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment related morbidity is a constant source of concern, for physicians and patients alike. PET adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, whilst minimising toxicities. The aim of this review is to digest the plethora of studies recently conducted and provide some clear, evidence-based practice statements to simplify the management HL. This article is protected by copyright. All rights reserved. Dept of Haematology, Gold Coast University Hospital, QLD. Griffiths University, QLD. Department of Radiation Oncology, Melbourne, Victoria. Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria. Fiona Stanley Hospital, Perth, WA. University of Western Australia, WA. ACT Pathology and Canberra Hospital, ACT. Austin Hospital, Melbourne, Victoria, Australia. Genesiscare, Gold Coast, QLD, Australia. Bond University, Gold Coast, QLD, Australia. Monash Health, Melbourne, Victoria, Australia. School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia. Dept of Haematology and Oncology, Western Health, Melbourne, Victoria, Australia. Andrew Love Cancer Centre, University Hospital Geelong, Melbourne, Victoria, Australia. Royal Darwin Hospital, Northwest Territories, Canada. Flinders Medical Centre, Adelaide, South Australia. Concord Repatriation General Hospital, Sydney, New South Wales, Australia. University of Sydney, Sydney, New South Wales, Australia. Department of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia. University of NSW, Sydney, New South Wales, Australia. Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia. Sir Peter MacCalllum Department of Oncology, the University of Melbourne, Victoria, Australia.

Similar Items